@article{036a8068705d42839dedc1b7013f3414,
title = "Characterization of First-line use of Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors in Metastatic Breast Cancer among Florida Health Care Systems",
abstract = " L. Raez; J. Unzaga; J. Garcia; K. Paranjpe; I. Arias; A. Castrellon ",
author = "Reshma Mahtani",
note = "e19347 Background: First-line treatment with a CDK4/6 inhibitor in combination with an aromatase inhibitor for HR+/HER2- postmenopausal metastatic breast cancer (mBC) is considered standard of care based on the compelling data across all landmark trials.",
year = "2020",
month = may,
day = "25",
language = "American English",
volume = "38",
journal = "Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting",
}